- Home
- AIRT vs XGN Comparison
AIRT vs XGN Comparison
Compare AIRT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- XGN
- Stock Information
- Founded
- AIRT 1980
- XGN 2002
- Country
- AIRT United States
- XGN United States
- Employees
- AIRT N/A
- XGN N/A
- Industry
- AIRT Air Freight/Delivery Services
- XGN Medical Specialities
- Sector
- AIRT Consumer Discretionary
- XGN Health Care
- Exchange
- AIRT Nasdaq
- XGN Nasdaq
- Market Cap
- AIRT 45.6M
- XGN 49.4M
- IPO Year
- AIRT N/A
- XGN 2019
- Fundamental
- Price
- AIRT $16.88
- XGN $2.78
- Analyst Decision
- AIRT
- XGN Buy
- Analyst Count
- AIRT 0
- XGN 1
- Target Price
- AIRT N/A
- XGN $7.00
- AVG Volume (30 Days)
- AIRT 19.7K
- XGN 22.2K
- Earning Date
- AIRT 11-11-2024
- XGN 11-11-2024
- Dividend Yield
- AIRT N/A
- XGN N/A
- EPS Growth
- AIRT N/A
- XGN N/A
- EPS
- AIRT N/A
- XGN N/A
- Revenue
- AIRT $281,814,000.00
- XGN $56,660,000.00
- Revenue This Year
- AIRT N/A
- XGN $9.98
- Revenue Next Year
- AIRT N/A
- XGN $13.63
- P/E Ratio
- AIRT N/A
- XGN N/A
- Revenue Growth
- AIRT 5.20
- XGN 7.05
- 52 Week Low
- AIRT $12.53
- XGN $1.30
- 52 Week High
- AIRT $30.60
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- AIRT 39.60
- XGN 46.20
- Support Level
- AIRT $16.69
- XGN $2.64
- Resistance Level
- AIRT $17.50
- XGN $2.83
- Average True Range (ATR)
- AIRT 1.00
- XGN 0.16
- MACD
- AIRT 0.19
- XGN -0.02
- Stochastic Oscillator
- AIRT 30.94
- XGN 28.41
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.